Leading Pathology Laboratories Deploy Tele-Diagnostics with Philips During the COVID-19 Pandemic

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced leading pathology laboratories across North America, Europe, and Asia have implemented full digitization for their histology samples based on the Philips Digital Pathology scanner and imaging-informatics solutions. Digital images are required to unlock the potential of digital pathology. Remote reviewing of pathological cases is essential to prevent delay in critical patient diagnosis and care, particularly during COVID-19.

During the pandemic, many pathologists, oncologists, and radiologists continued their work from home. This created an unprecedented need for home workstations and secure clinical informatics solutions allowing clinicians to read images remotely and enabling real-time virtual collaboration between their multi-disciplinary care teams. Pre-COVID-19, pathology labs that digitized their workflows across different sites reported improved collaboration and an average productivity gain of 21%.

Examples of leading pathology laboratories that recently transformed towards a digital workflow with Philips IntelliSite Pathology Solution are: Mackenzie Health (Canada), Pathology Institute Tel Aviv Sourasky MC (Israel), University Medical Center Groningen (Netherlands), St. Olavs Hospital (Norway), Singapore General Hospital SGH (Singapore), Oxford University Hospitals NHS (UK), and NHS Ayrshire & Arran (UK).

"As healthcare becomes more complex and demanding, digitization has become a key enabler for the hospital to provide better care for our patients and to be more efficient. Digital pathology is an example, and our partnership with companies such as Philips with the clinical and technical know-how is important in helping us achieve our goal," said Prof. Kenneth Kwek, Chief Executive Officer at Singapore General Hospital SGH.

"COVID-19 has become a catalyst for change - a defining moment for all of us to reimagine healthcare the way it should be," said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. "With a focus on the people at the center of cancer care, we work to innovate workflows, remove barriers of fragmented systems, and bring insights directly to care providers to support excellent cancer care."

Shared decision-making, pathway selection and treatment

Philips' solutions for oncology and digital pathology can help transform and enhance the multi-disciplinary workflows, including the oncology tumor board and care pathways process. Critical patient data is integrated for both oncologists, radiologists and pathologists, allowing them to collaborate efficiently, even when working remotely. The Philips platform supports streamlined preparation, enhances review and analysis, and empowers the cancer care team to reach clinical treatment decisions based on disease-specific dashboards, diagnostic images, reports, and structured patient data. Visit Philips Digital Pathology for more information on how Philips is enhancing digital pathology workflows. Visit Philips Live at RSNA 2020 to learn how Philips integrated workflow solutions connect data, technology and people across the diagnostic enterprise, helping to redefine radiology workflow efficiencies.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries.

Most Popular Now

Study Details First Artificial Intellige…

Hospital-based laboratories and doctors at the front line of the COVID-19 pandemic might soon add artificial intelligence to their testing toolkit. A recent study conducted with collaborators from the University...

Accelerating Data Solutions to Save LIVE…

The consortium of COVID-X announces the launch of the ​1st Open Call ​framed in a ​2-year initiative that will invest ​4 million € to fast-track to market 30+ European data...

Significant Disparities in Telemedicine …

After "COVID-19," the term that most people will remember best from 2020 is likely to be "social distancing." While it most commonly applied to social gatherings with family and friends...

Model Used to Evaluate Lockdowns was Fla…

In a recent study, researchers from Imperial College London developed a model to assess the effect of different measures used to curb the spread of the coronavirus. However, the model...

New Virtual Screening Strategy Identifie…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang...

Using Artificial Intelligence to Find Ne…

Scientists have developed a machine-learning method that crunches massive amounts of data to help determine which existing medications could improve outcomes in diseases for which they are not prescribed. The intent...

One in Four Doctors Attacked, Harassed o…

While many physicians benefit from social media by networking with potential collaborators or interfacing with patients, a new study from Northwestern University and the University of Chicago found many physicians...

CliniSys Launches Laboratory Information…

CliniSys has launched a new laboratory information management system for genomic laboratories in the UK. The company has brought GLIMS Genomics to the UK from Europe, where it is being...

The Institute of Healthcare Management C…

The Institute of Healthcare Management has called for honest and open communication about NHS capacity after a snapshot survey revealed the scale of sickness absence across the service. The UK's leading...

FDA Releases Artificial Intelligence / M…

Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach...

First NHS Trust and Sectra Achieve Rapid…

A new region-wide approach to analysing x-rays, MRI scans, CT scans, mammography, and an entire range of crucial diagnostic images, has started to become reality, now that The Pennine Acute...